Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology RydaptⓇ - Multi-targeted kinase inhibitor 2023 priorities Innovation: Clinical trials Neuroscience NCT03591510 (CPKC412A2218) Acute myeloid leukemia, pediatrics Indication Phase Phase 2 Patients 20 Primary Outcome Measures Arms Intervention Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Target Patients Readout 2026 Milestone(s) Publication TBD Oncology Appendix Abbreviations Other 91 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation